PwC recently launched M&A 1H2019 review - China pharmaceuticals and medical devices sectors which reviews numerous M&A data and cases in the pharmaceutical and medical device industry in 2019. In general, China pharmaceutical M&A was relatively active, and the volume and value are both increased. Meanwhile, the deal value of China medical device M&A decreased significantly, which were the lowest during the past 5 years.
China pharmaceutical M&A was relatively active in 1H19, with a 35% increase in deal volume and a 45% increase in deal value at US$10.8 billion. Overall deal volume reached 242, close to the highest seen in 1H18 (258), with activities from domestic strategic buyer almost doubled from 2H18.
China medical device M&A in 1H19 decreased by 89% to merely $769m, which were the lowest during the past 5 years. No mega deals were conducted by domestic strategic buyer or PE while outbound deal almost froze. The volume of domestic strategic M&A increased by 33% but the value decreased by 43% to $615m, there were only 3 deals with value over $100m.
© 2003 - 2019 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.